Compare Natera Inc. Common Stock (NTRA) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $286.02 (market cap $48.39B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| NTRA | WAB | |
|---|---|---|
Market Cap | $57.03B | $48.39B |
Volume | 1,131,157 | 960,464 |
Sector | Health | Industrials |
52-Week High | $425.64 | $305.79 |
52-Week Low | $179.42 | $193.43 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $56.18B | $54.30B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
